The roX1 and roX2 genes of Drosophila produce non-coding transcripts that localize to the X-chromosome. In spite of their lack of sequence similarity, they are redundant components of an RNA/protein complex that up-regulates the male X-chromosome, contributing to the equalization of X-linked gene expression between males and females. roX1 is detected at 2 h AEL, prior to formation of the complex, and is present in both sexes. Maternally provided MLE (Maleless) is required for roX1 stability. By contrast, roX2 is male-specific and is first observed at 6 h. Either roX transcript can support X-localization of the complex, but localization is delayed in roX1 mutants until roX2 expression. These results support a model for the ordered assembly of the complex in embryos. q
Introduction
Organisms with divergent sex chromosomes, such as X and Y, must equalize the expression of X-linked genes between the sexes. This is the most immediate and vital aspect of sexual differentiation, and its failure is typically lethal. A component of this process in Drosophila melanogaster is the two-fold up-regulation of most of the genes residing on the single X-chromosome of males. This occurs through the action of a male-limited complex composed of the five male-specific lethal gene products (MSL proteins) and JIL-1 kinase (Cline and Meyer, 1996; Hilfiker et al., 1997; Jin et al., 2000) . This complex binds to the X-chromosome and directs acetylation of histone H4 on lysine 16 (H4Ac16), a modification linked to elevated gene expression Corona et al., 2002; Smith et al., 2000) . The X-linked, non-coding, male-specific roX1 and roX2 RNAs are also required for dosage compensation. Both transcripts colocalize with the MSL proteins in a finely banded pattern along the length of the polytenized salivary gland X-chromosome (Franke and Baker, 1999; Gu et al., 2000; Meller et al., 2000; Meller et al., 1997) . The absence of a male phenotype associated with roX1 mutations suggested that the roX1 and roX2 transcripts might be functionally redundant in spite of their lack of sequence similarity (Amrein and Axel, 1997; Franke and Baker, 1999; Meller et al., 1997) . In support of this model, a roX2 deletion is also without male phenotype but the partial excision mutant roX1 ex6 combined with the roX2 deletion produced a striking, male-specific decrease in viability resulting from a failure of dosage compensation (Meller and Rattner, 2002) . The observation that a wild type copy of either roX1 or roX2 can support localization of the MSL complex to the X-chromosome suggests functional interchangeability. However, roX2, but not roX1, can spread to other sites on the X-chromosome in the absence of the MSL3 protein, suggesting that the roX transcripts may also have independent functions. A model of the ordered assembly of the MSL complex that was based on this observation placed roX2 before roX1 (Meller et al., 2000) .
The initiation of dosage compensation in embryos provides an opportunity to test the ordered assembly model. X-localization of the protein and RNA components of the dosage compensation complex can be observed in wild type male embryos at 3 h AEL. This slightly precedes the accumulation of H4Ac16 on the X-chromosome. Assembly of the complex is triggered by male-limited zygotic production of MSL2, and initially relies on maternal supplies of the other necessary proteins (Rastelli et al., 1995) . Embryos collected from females mutated for each of the msl genes can be used to assess the requirement for maternal supplies of that particular gene product in the early steps of roX RNA transcription and complex assembly. Similarly, localization of the MSL proteins to the X-chromosome of male embryos with roX mutations can be used to evaluate the role of roX1 and roX2 in this process.
Although roX1 and roX2 appear identical in expression in male larvae and adults, their transcription differs strikingly during embryogenesis. Absent from newly deposited embryos, roX1 is strongly expressed in both sexes during formation of the blastoderm at 2 h, and transcripts gradually disappear from females midway through embryogenesis (Meller et al., 1997) . By contrast, roX2 is first detected at 6 h and is restricted to males. Both wild type embryos and those deleted for roX2 show localization of MSL2 to subnuclear foci around 3 h. However, males mutated for roX1 delay MSL2 localization until after roX2 expression. Strong X-localization was not detected in embryonic males bearing a chromosome mutated for both roX genes, supporting previous findings (Franke and Baker, 1999) . Early transcription of roX1 was independent of maternally supplied MSL proteins. However, in embryos collected from mle 1 mothers, roX1 was unstable and disappeared during gastrulation. This suggests that MLE and roX1 form an initial complex necessary for roX1 stability. These results support the functional interchangeability of the roX transcripts for the initiation of dosage compensation, and suggest a model in which an interaction between maternal MLE and zygotic roX1 is an initial step preceding the formation of the dosage compensation complex in embryos.
Results
2.1. Expression of roX1 and roX2 are dissimilar in embryos roX1 has been reported to be male-limited in embryos, but expression in both sexes has also been observed. An intriguing possibility was that these conflicting reports were attributable to the presence of antisense transcripts in females. These would have been detected by the double stranded DNA probes used in the initial study (Meller et al., 1997) , but would not have been detected by the single stranded riboprobes subsequently used (Franke and Baker, 1999) . To address this possibility in situ analysis was repeated using sense and antisense RNA probes to the roX1 region. No roX1 signals were detected in preblastoderm embryos (Fig. 1A,B) . Antisense roX1 probes detected transcript in embryos at the blastoderm stage (Fig. 1C,D , G) . Male and female embryos may be distinguished by the use of a female-specific LacZ reporter (Keyes et al., 1992) . Following X-Gal staining, both male and female embryos expressing roX1 were readily identified (Fig. 1E) . No transcripts overlapping the roX1 gene were detected using sense riboprobes (data not shown; see Section 4 for descriptions of the probes used). Although roX1 RNA is transcribed in embryos of both sexes, roX1 expression is strikingly male-preferential in larvae and adults. Loss of the roX1 transcript from females mid way through embryogenesis has been noted (Meller et al., 1997) , and the onset of sex-specific roX1 expression is consistent with the reduction in signal from an antisense roX1 probe at 10 h AEL (Fig. 1G) .
By contrast, roX2 is much less strongly expressed in embryos and is undetectable before 6 h. In wild type populations, 50% of older embryos have roX2 signal and these are invariably male, as revealed by in situ hybridization to embryos carrying the LacZ reporter (Fig. 1F,G) . Although the roX1 and roX2 probes used in these studies produce signals of similar strength when hybridized to salivary glands from third instar male larvae, roX2 staining of embryos was much weaker than roX1 staining (see Section 4 for details of histology). This indicates that the relative levels of roX1 and roX2 transcripts shift as development proceeds, with roX1 prominent during embryogenesis and the two roX RNAs becoming more equivalent in the third larval instar.
roX expression precedes dosage compensation
Localization of the MSL proteins to the salivary gland Xchromosome requires formation of the intact complex, and hence the presence of all the MSL proteins (Chang and Kuroda, 1998; Gorman et al., 1995; Lyman et al., 1997; Palmer et al., 1994) . At least one roX RNA is similarly required for localization in larvae, and a prior study using roX1 mb710 combined with an embryonic lethal deletion removing roX2 suggested that one roX gene was also required for localization in male embryos (Franke and Baker, 1999) . However, this study used deletions also removing the largest subunit of RNA polymerase II (RPII215) which is less than 10 kb distal to roX2. The resulting disruption in zygotic gene expression may affect dosage compensation non-specifically. The requirement for roX transcripts was therefore determined in embryos mutated for each of the roX genes, but otherwise fully viable.
Previous studies have documented the male-specificity of MSL2 immunoreactivity in embryos, and have established that MSL2 can first be detected localizing to the X-chromosome at the end of the blastoderm stage, about 3 h AEL. X-localization, which is dependent on the presence of all of the MSL proteins, precedes the onset of dosage compensation as detected by enrichment of H4Ac16 (Franke et al., 1996; McDowell et al., 1996; Rastelli et al., 1995) . X-chromosome localization produces a characteristic punctate MSL immunostaining pattern that is readily distinguished from non-localized immunoreactivity (see Rastelli et al. (1995) ). As expected, anti-MSL2 antibodies labeled , 50% of gastrulating wild type embryos ( Fig. 2A,B) , and the appearance of punctate staining indicative of X-chromosome localization could be clearly observed in males older than 3 h AEL (Fig. 2D ). Populations of embryos in which all males were of identical genotype were produced, thus simplifying the scoring of stained preparations. One-third of the developing embryos from these collections are male, and MSL2 immunoreactivity was detected in the anticipated proportion of embryos (see Section 4). Embryos in which MSL2 was detected with HRP were scored for developmental stage and localized staining. When males carry wild type roX genes, the appearance of punctate MSL2 immunoreactivity is first detected at 3 h and is observed in approximately one-third of older embryos (Fig. 3A) . Df(1)52 is a deficiency of less than 30 kb that removes roX2 and several closely linked essential genes, including RPII215 (Meller and Rattner, 2002 restores the normal timing of MSL2 localization in Df(1)52 males (Fig. 3B, closed circles) . The roX2 gene is therefore unnecessary for the initial formation of the MSL complex or its localization. However, disruption of development by deletion of the region surrounding roX2 delays the onset of MSL2 localization in a manner unrelated to the presence of the roX2 gene. The timing of MSL2 localization suggested that roX1 could be necessary for initial X-localization of the dosage compensation complex. This was tested by determining the timing of MSL2 localization in roX1 ex6 males. The roX1 ex6 allele was created by an imprecise excision removing 1.4 kb from the 5 0 end of the gene. roX1 RNA is not detected in larvae or adults carrying this allele. Although MSL2 could be detected in one-third of the developing embryos from these collections, it did not appear in a punctate pattern until 7 h (Fig. 3C) . Therefore, in roX1 ex6 males there is a 4 h lag in localization of the complex, which now follows shortly after roX2 expression. X-chromosomes mutated for both roX genes were used to determine the ability of MSL2 to localize in the absence of any wild type roX RNA. MSL2 expression is detected in these embryos (Fig. 2C ), but the strong foci normally observed upon localization of the MSL complex to the X-chromosome were not observed in roX1 ex6 roX2 2 males (Fig. 3D) . However, weak foci of MSL2 staining could be detected in some mutant embryos during germ band retraction, and these are more apparent when detected by immunofluorescence (compare Fig. 2E and H). Although differing from the more consistent and intense foci observed in wild type males, the presence of weak foci in roX1 ex6 roX2 2 embryos indicates that MSL2 retains some ability to localize within the nucleus, even in the absence of a wild type roX gene. This is consistent with the observation that, although strikingly reduced, some Xlocalization of MSL2 is retained on polytene preparations from roX1 ex6 roX2 2 males (Meller and Rattner, 2002) .
roX1 requires maternal MLE for stability
During larval and adult stages roX1 is highly unstable in the absence of an intact dosage compensation complex (Meller et al., 2000) . The embryonic transcription of roX1 precedes expression of MSL2 and formation of the complex, yet roX1 appears stable in embryos. In addition, until 10 h AEL roX1 transcripts are detected in female embryos, which lack MSL2. With the exception of MSL2, the MSL proteins are maternally provisioned and support the formation of the initial dosage compensation complexes (Rastelli et al., 1995) . To test the hypothesis that one or more of these maternal proteins are responsible for roX1 stability, roX1 was examined in embryos from mothers homozygous for mutations in each of the msl genes. As anticipated, the maternal genotype with respect to the missense msl2 1 mutation had no effect. Early roX1 expression was also unchanged in embryos from females homozygous for a null allele of male-specific lethal 1 (msl1 L60 , a 2 kb deletion removing most of the coding region), male-specific lethal 3 (msl3 2 ), and males absent on first (mof 1 and mof 2 , missense and nonsense mutations, respectively; data not shown). By contrast, although an initial burst of roX1 expression was detected in blastoderm stage embryos produced by mothers homozygous for the nonsense mle 1 mutation, roX1 disappeared upon gastrulation (Fig. 4A -C) . Between 4 and 5 h, roX1 can once more be detected. MLE is a member of the DExH family of helicases, and has RNA and DNA helicase activity in vitro (Lee et al., 1997) . Interestingly, a similar lack of roX1 stability was detected in embryos expressing the mutated MLE DQIH protein that lacks helicase activity, indicating that this activity is required for roX1 stability (data not shown; Lee et al., 1997) . MLE has also been linked to the ability of the roX transcripts to travel from their sites of synthesis on the polytene X-chromosome (Meller et al., 2000) . In embryos from mle 1 mothers, spots of transcription within blastoderm nuclei are particularly apparent, and embryos displaying either one or two sites of synthesis per nucleus are readily observed (Fig. 4D,E) . This suggests that MLE is also required to move roX1 from its site of synthesis in embryos. These results demonstrate that none of the MSL proteins are required for initial roX1 transcription, but maternal stores of MLE contribute to roX1 RNA stability in early embryos.
Discussion
The roX transcripts are male-specific in larvae and adults, however, they are not under the control of the tra and tra 2 sex determination genes (Amrein and Axel, 1997; Meller et al., 1997) . Antisense and non-coding transcripts have been detected at imprinted mammalian loci and mediate inhibitory regulation of closely linked transcripts (Lee et al., 1999; Luikenhuis et al., 2001; Sleutels et al., 2002; Wutz et al., 1997) . The presence of antisense roX1 transcripts in females would explain conflicting reports of roX1 expression during embryogenesis and could also be relevant to the establishment of sex-specific roX1 transcription. However, single stranded RNA probes detect no evidence of antisense roX1 transcripts, and the present data supports the initial contention that roX1 is transcribed in all blastoderm stage embryos (Meller et al., 1997) .
roX2, but not roX1, can move to many sites on polytene X-chromosomes in the absence of MSL3, suggesting that these transcripts have distinct functionality in assembly or localization of the complex (Meller et al., 2000) . The differences between roX1 and roX2 expression during embryogenesis further implied that these RNAs might fulfil different functions during the establishment of dosage compensation. Removal of the primary early source of roX RNA by the roX1 ex6 mutation delays the onset of a punctate MSL2 staining pattern, which indicates X-localization, until roX2 is transcribed several hours later. Therefore, roX2 can support a delayed initiation of dosage compensation, and will do so if roX1 is unavailable. The temporal linkage of roX2 RNA expression to the localization of MSL2 in roX1 mutants, and the more profound disruption of MSL2 localization by mutation of both RNAs, support prior assertions that one of these RNAs is required for correct targeting of the dosage compensation complex to the male X-chromosome in embryos and larvae (Franke and Baker, 1999; Meller and Rattner, 2002) . In spite of the striking differences in the timing, amount and sexspecificity of roX1 and roX2 during embryogenesis, these transcripts appear interchangeable in their ability to direct the initiation of dosage compensation.
The occasional observation of weak foci of MSL2 staining in older male embryos carrying X-chromosomes mutated for both of the roX genes suggests either that roX RNA is not absolutely essential for localization of the dosage compensation complex, or that the roX1 ex6 allele, a partial excision, retains some ability to produce functional transcripts, or that other genes produce transcripts which can partially support complex assembly and localization. All of these theories have been previously raised to account for a low level of developmentally delayed adult male escapers that are roX1 ex6 roX2 2 (Meller and Rattner, 2002) . The findings of this study will support a model for the assembly of dosage compensation complexes during embryogenesis. roX1, highly expressed in all blastoderm stage embryos, is transcribed in advance of MSL2 translation and is likely to form an initial complex with MLE. It is possible that several of the MSL proteins must contact roX1 during assembly of the complex. In all, three members of the dosage compensation complex, MLE, MSL3 and MOF, have been reported to have RNA binding activity in vitro, or to be removed from the X-chromosome by RNase A digestion Richter et al., 1996) . With the exception of MSL2, all of the MSL proteins are present upon initial transcription of roX1 at 2 h AEL. The onset of dosage compensation has been linked to the male-limited production of MSL2 about 3 h AEL. This sequence of events suggests that MSL2 may complete a complex that is already organized by several RNA-binding proteins and the roX1 transcript. The proposed primary association between roX1 and MLE could reflect a need for the MLE helicase activity to disrupt incorrect base pairing or RNA/protein interactions preventing the large roX1 transcripts from correctly assembling with the other RNAbinding proteins of the dosage compensation complex.
Experimental procedures

Drosophila strains
Drosophila were maintained on a standard cornmeal and molasses diet in a humidified incubator at 25 8C. Mutations in roX1 and roX2 have been previously described (Kelley et al., 1999; Meller and Rattner, 2002) . The missense mutation msl2 1 (Zhou et al., 1995) , null msl1 L60 (Chang and Kuroda, 1998) , the missense mof 1 and nonsense mof 2 , mutations (Gu et al., 1998; Hilfiker et al., 1997) , and the nonsense mle 1 (Rastelli and Kuroda, 1998) have been described. msl3 2 , and mutations not specifically referenced in the text, are described (Lindsley and Zimm, 1992) .
Detection of roX expression by in situ hybridization
Normal expression of roX1 and roX2 was determined in mixed age collections of embryos from either a yw stock (wild type for the roX and the msl genes) or yw; [w þ Sxl Pe-LacZ] that had been stained with X-Gal (Keyes et al., 1992) . Embryos were dechorionated, fixed and stored as described (Meller et al., 1997) . DIG-labeled roX1 and roX2 riboprobes were transcribed from linearized templates derived from the roX1 genomic region or from a full-length roX2 cDNA (Amrein and Axel, 1997) . Sense probes were transcribed from genomic DNA subclones overlapping 1.5 kb of the 5 0 end of roX1 (Eco R1-Pvu II fragment), 1.1 kb of the 3 0 end of roX1 (Sma1-Eco R1 fragment) and a 2.6 kb Xho I-Hind III fragment 1.4 kb upstream from the transcription start site. Antisense probes hybridizing to 1.8 kb at the 5 0 end of roX1 (Eco RI-Bgl II fragment), 1.4 kb at the 5 0 end (Pvu II-Bgl II fragment), 3.3 kb of the 3 0 end (Pvu II-Eco RI fragment) and 0.8 kb at the 3 0 end (Xmn IEco RI fragment) were used with similar success on wild type tissues. Probes were assayed for DIG incorporation, and estimations of the relative levels of roX1 and roX2 were performed using probes containing equivalent amounts of DIG. Alkaline phosphatase color development was complete in 15 min when antisense roX1 probes were used, but this time was extended to at least 45 min when the much less abundant embryonic roX2 transcripts were being visualized. In situ hybridization was otherwise performed as previously described (Meller and Rattner, 2002) .
Immunolocalization of MSL2 in embryo populations with roX
2 males Antibody staining of embryos was performed essentially as previously described (Rastelli et al., 1995) . Detection utilized a rabbit anti-MSL2 antibody that was visualized with a Vectastain ABC kit (Vector Laboratories, Burlingame CA), or with a Texas Red-conjugated goat anti-rabbit second antibody (ICN Pharmaceuticals). Identical exposure times were used when comparing MSL immunostaining in embryos from different genetic backgrounds.
Mating C(1)DXyf/Y females with XY males yields 4 classes of zygotes in equal numbers: XXX and XXY females, neither of which expresses MSL2; males carrying the paternal X and maternal Y chromosomes; and YY zygotes. The last class displays overtly abnormal development and was eliminated from analysis. Consequently, onethird of embryos undergoing normal development will be males, an expectation supported by MSL2 immunoreactivity in embryos from these collections. Populations in which all males carried a mutated X-chromosome were produced by mating males with the desired X-chromosome to attached X females (C ( 
Staging of embryos, photography and presentation of data
Staging of embryos relied on published developmental schedules (Campos-Ortega and Hartenstein, 1997). The present study recognizes stages that vary in length from 10 min to 1.5 h, a source of disparity in the number of individual embryos comprising each data point. Unless otherwise noted, at least 20 individuals contributed to each point. Visualization and photography was done with a Zeiss Axioscope 2 fitted with an Axiophot photography system.
